- Home
- DKL vs APLS Comparison
DKL vs APLS Comparison
Compare DKL & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DKL | APLS |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | DKL | APLS |
|---|---|---|
| Price | $45.82 | $23.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 19 |
| Target Price | ★ $45.50 | $33.11 |
| AVG Volume (30 Days) | 63.1K | ★ 2.4M |
| Earning Date | 11-07-2025 | 10-30-2025 |
| Dividend Yield | ★ 9.78% | N/A |
| EPS Growth | ★ 9.17 | N/A |
| EPS | ★ 3.09 | 0.36 |
| Revenue | $967,420,000.00 | ★ $1,016,397,000.00 |
| Revenue This Year | $12.80 | $29.00 |
| Revenue Next Year | $11.50 | N/A |
| P/E Ratio | ★ $14.82 | $65.98 |
| Revenue Growth | N/A | ★ 42.11 |
| 52 Week Low | $34.59 | $16.10 |
| 52 Week High | $48.00 | $35.72 |
Technical Indicators
Market Signals| Indicator | DKL | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.62 | 62.06 |
| Support Level | $45.10 | $20.51 |
| Resistance Level | $46.93 | $21.72 |
| Average True Range (ATR) | 1.10 | 0.81 |
| MACD | 0.08 | 0.51 |
| Stochastic Oscillator | 72.16 | 92.66 |
Price Performance
Historical ComparisonAbout DKL Delek Logistics Partners L.P. Common Units representing Limited Partner Interests
Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.